Oppenheimer Raises Prestige Consumer Healthcare (NYSE:PBH) Price Target to $93.00

Prestige Consumer Healthcare (NYSE:PBH) had its target price hoisted by Oppenheimer from $87.00 to $93.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research analysts have also issued reports on PBH. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average price target of $92.60.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $85.68 on Thursday. The firm has a market capitalization of $4.23 billion, a PE ratio of 20.07, a PEG ratio of 2.43 and a beta of 0.50. The company has a current ratio of 3.68, a quick ratio of 2.10 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $88.36. The business’s 50 day moving average is $79.27 and its 200-day moving average is $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Sell-side analysts predict that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $27,000. CIBC Private Wealth Group LLC lifted its position in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after purchasing an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. nVerses Capital LLC increased its holdings in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Finally, Huntington National Bank raised its position in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.